Arkadios Wealth Advisors Purchases New Position in VanEck Pharmaceutical ETF $PPH

Arkadios Wealth Advisors purchased a new position in VanEck Pharmaceutical ETF (NASDAQ:PPH) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 7,780 shares of the company’s stock, valued at approximately $684,000.

Other hedge funds also recently bought and sold shares of the company. U.S. Capital Wealth Advisors LLC increased its position in shares of VanEck Pharmaceutical ETF by 5.8% in the second quarter. U.S. Capital Wealth Advisors LLC now owns 2,750 shares of the company’s stock valued at $242,000 after buying an additional 150 shares in the last quarter. CWM LLC grew its stake in VanEck Pharmaceutical ETF by 167.9% in the 2nd quarter. CWM LLC now owns 375 shares of the company’s stock valued at $33,000 after acquiring an additional 235 shares during the period. Harbour Investments Inc. grew its stake in VanEck Pharmaceutical ETF by 9.7% in the 2nd quarter. Harbour Investments Inc. now owns 4,450 shares of the company’s stock valued at $391,000 after acquiring an additional 394 shares during the period. Axxcess Wealth Management LLC increased its holdings in VanEck Pharmaceutical ETF by 4.8% in the 2nd quarter. Axxcess Wealth Management LLC now owns 9,114 shares of the company’s stock worth $802,000 after acquiring an additional 416 shares in the last quarter. Finally, AE Wealth Management LLC raised its position in VanEck Pharmaceutical ETF by 118.4% during the first quarter. AE Wealth Management LLC now owns 1,046 shares of the company’s stock worth $95,000 after acquiring an additional 567 shares during the period.

VanEck Pharmaceutical ETF Stock Up 0.3%

Shares of NASDAQ PPH opened at $92.84 on Tuesday. The firm has a market cap of $1.16 billion, a price-to-earnings ratio of 20.21 and a beta of 0.54. The company’s 50-day simple moving average is $90.54 and its 200-day simple moving average is $88.35. VanEck Pharmaceutical ETF has a 52-week low of $77.67 and a 52-week high of $95.13.

VanEck Pharmaceutical ETF Cuts Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, October 6th. Shareholders of record on Wednesday, October 1st were paid a dividend of $0.3931 per share. This represents a $1.57 annualized dividend and a yield of 1.7%. The ex-dividend date was Wednesday, October 1st.

VanEck Pharmaceutical ETF Company Profile

The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.